Yadong Xu1,2,3, Qiong Song3,4, Laura E Pascal3, Mingming Zhong3, Yibin Zhou3,5, Jianhua Zhou3, Fang-Ming Deng6, Jiaoti Huang7, Zhou Wang3,8,9. 1. Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China. 2. The Third Xiangya Hospital of Central South University, Changsha, China. 3. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 4. Center for Translational Medicine, Guangxi Medical University, Nanning, China. 5. Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, China. 6. Department of Pathology, NYU School of Medicine, New York, New York. 7. Department of Pathology, Duke University School of Medicine, Durham, North Carolina. 8. UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 9. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: DHX15 is a member of the DEAH-box (DHX) RNA helicase family. Our previous study identified it as an AR coactivator which contributes to prostate cancer progression. METHODS: We investigated DHX15 expression in castration resistant prostate cancer specimens and the influence of DHX15 on the responsiveness of prostate cancer cells to DHT stimulation. We also explored the role DHX15 played in enzalutamide resistance and the interacting domain in DHX15 with AR. DHX15 expression level in human CRPC specimens and prostate cancer specimens was detected by tissue microarray (TMA) immunostaining analysis. Colony formation assay was performed to determine the proliferation of cells treated with enzalutamide or DHT. siRNAs were used to knockdown DHX15. The interactions between DHX15 and AR were detected using co-immunoprecipitation assay. RESULTS: The expression level of DHX15 was upregulated in human CRPC specimens compared with hormone naïve prostate cancer specimens. DHX15 knockdown reduced AR sensitivity to low DHT concentrations in C4-2 cells. Inactivation of DHX15 sensitizes the enzalutamide treatment in C4-2 cells. Deletion mutagenesis indicated that DHX1 5 interacts with AR through its N terminal domain. CONCLUSIONS: These findings suggest that DHX15 contributes to prostate cancer progression. DHX15 is required for androgen receptor sensitivity to low DHT concentrations and contributes to enzalutamide resistance in C4-2 cells. Targeting DHX15 may improve the ADT treatment.
BACKGROUND:DHX15 is a member of the DEAH-box (DHX) RNA helicase family. Our previous study identified it as an AR coactivator which contributes to prostate cancer progression. METHODS: We investigated DHX15 expression in castration resistant prostate cancer specimens and the influence of DHX15 on the responsiveness of prostate cancer cells to DHT stimulation. We also explored the role DHX15 played in enzalutamide resistance and the interacting domain in DHX15 with AR. DHX15 expression level in human CRPC specimens and prostate cancer specimens was detected by tissue microarray (TMA) immunostaining analysis. Colony formation assay was performed to determine the proliferation of cells treated with enzalutamide or DHT. siRNAs were used to knockdown DHX15. The interactions between DHX15 and AR were detected using co-immunoprecipitation assay. RESULTS: The expression level of DHX15 was upregulated in human CRPC specimens compared with hormone naïve prostate cancer specimens. DHX15 knockdown reduced AR sensitivity to low DHT concentrations in C4-2 cells. Inactivation of DHX15 sensitizes the enzalutamide treatment in C4-2 cells. Deletion mutagenesis indicated that DHX1 5 interacts with AR through its N terminal domain. CONCLUSIONS: These findings suggest that DHX15 contributes to prostate cancer progression. DHX15 is required for androgen receptor sensitivity to low DHT concentrations and contributes to enzalutamide resistance in C4-2 cells. Targeting DHX15 may improve the ADT treatment.
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Elahe A Mostaghel; Brett T Marck; Stephen R Plymate; Robert L Vessella; Stephen Balk; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery Journal: Clin Cancer Res Date: 2011-08-01 Impact factor: 12.531
Authors: G N Thalmann; P E Anezinis; S M Chang; H E Zhau; E E Kim; V L Hopwood; S Pathak; A C von Eschenbach; L W Chung Journal: Cancer Res Date: 1994-05-15 Impact factor: 12.701
Authors: Steven Kregel; James L Chen; Westin Tom; Venkatesh Krishnan; Jacob Kach; Hannah Brechka; Tim B Fessenden; Masis Isikbay; Gladell P Paner; Russell Z Szmulewitz; Donald J Vander Griend Journal: Oncotarget Date: 2016-05-03
Authors: Osama S Mohammad; Michael D Nyquist; Michael T Schweizer; Stephen P Balk; Eva Corey; Stephen Plymate; Peter S Nelson; Elahe A Mostaghel Journal: Cancers (Basel) Date: 2017-12-06 Impact factor: 6.639
Authors: Shuyi Fang; Jake L Owens; Elena Beketova; Sheng Liu; Xufeng Chen; Qingfu Zhang; Andrew M Asberry; Xuehong Deng; Jonathan Malola; Jiaoti Huang; Chenglong Li; Roberto Pili; Bennett D Elzey; Timothy L Ratliff; Jun Wan; Chang-Deng Hu Journal: Cancer Res Date: 2020-09-30 Impact factor: 12.701